Intellia Therapeutics, Inc. (NTLA) Position Maintained by Artal Group S.A.
Artal Group S.A. held its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 250,000 shares of the company’s stock at the close of the 2nd quarter. Artal Group S.A. owned about 0.69% of Intellia Therapeutics worth $4,000,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in NTLA. SG Americas Securities LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter worth about $101,000. IHT Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics during the first quarter worth about $117,000. Bank of Montreal Can increased its position in shares of Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Intellia Therapeutics by 117.7% during the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after acquiring an additional 4,351 shares during the last quarter. Finally, Nisa Investment Advisors LLC purchased a new stake in shares of Intellia Therapeutics during the second quarter worth about $134,000. 46.52% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/intellia-therapeutics-inc-ntla-position-maintained-by-artal-group-s-a.html.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded down 0.44% during trading on Tuesday, reaching $22.71. The company had a trading volume of 94,666 shares. The firm has a 50-day moving average price of $22.13 and a 200 day moving average price of $20.95. The stock’s market cap is $820.10 million. Intellia Therapeutics, Inc. has a 12-month low of $10.83 and a 12-month high of $23.58.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.03). The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm’s quarterly revenue was up 40.5% compared to the same quarter last year. Equities research analysts predict that Intellia Therapeutics, Inc. will post ($1.78) EPS for the current fiscal year.
A number of analysts have recently issued reports on the company. Barclays PLC assumed coverage on Intellia Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $29.00 target price on the stock. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a research note on Tuesday, August 29th. Cann reiterated a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 1st. Oppenheimer Holdings, Inc. initiated coverage on Intellia Therapeutics in a research note on Tuesday, July 18th. They issued a “market perform” rating for the company. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a research note on Saturday, July 22nd. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $25.43.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total transaction of $2,436,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.80% of the stock is currently owned by corporate insiders.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA).
Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.